Study guide

5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns

ARRT Radiation Therapy Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Patient Care & Education

1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation

2 Chapter 2: Radiation Physics, Radiobiology & Protection

2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients

3 Chapter 5: Treatment Sites, Tumors & Classification

5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems

4 Chapter 3: Treatment Planning & Dosimetry

3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances

5 Chapter 4: Treatment Delivery, Image Guidance & QA

4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation

5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns

Key Takeaways Explain This Topic AI

Esophageal SCC clusters in the cervical/upper-mid esophagus while adenocarcinoma clusters at the distal esophagus/GE junction from Barrett esophagus.

Pancreatic head tumors cause obstructive jaundice by compressing the common bile duct, and resectability depends on SMA/SMV/celiac axis involvement.

Radiation therapy has a defined role in rectal cancer (fixed pelvic organ, TME, neoadjuvant chemoradiation) but not in mobile colon cancer.

The Nigro protocol treats anal canal SCC with definitive chemoradiation to preserve the anal sphincter and avoid permanent colostomy.

Bladder-preservation trimodality therapy (TURBT + chemoradiation) requires a consistent bladder-filling protocol to control daily volume variation.

Last updated: July 2026

Esophageal Cancer

The esophagus is divided into cervical, upper/mid/lower thoracic, and gastroesophageal (GE) junction segments. Location drives histology and lymphatic spread patterns that the therapist must recognize when reviewing a simulation CT or a portal image.

Squamous cell carcinoma (SCC) predominates in the cervical and upper/mid thoracic esophagus and is linked to tobacco and alcohol use.

Adenocarcinoma predominates at the distal esophagus and GE junction, typically arising from Barrett esophagus (chronic reflux-induced columnar metaplasia).

Siewert classification describes GE-junction tumors by their center relative to the junction (Type I, II, III) and guides whether treatment follows an esophageal or gastric paradigm.

Lymphatic drainage is longitudinal and unpredictable — cervical tumors can drain to mediastinal nodes and distal tumors to celiac nodes, so elective nodal volumes are often generous along the length of the esophagus rather than site-restricted.

Standard management for locally advanced disease is trimodality therapy : neoadjuvant chemoradiation followed by esophagectomy (CROSS regimen), or definitive chemoradiation alone when surgery is not an option (cervical esophagus, medically inoperable patients).

Gastric Cancer

The stomach is subdivided into the cardia, fundus, body, antrum, and pylorus. Gastric adenocarcinoma is the dominant histology. Nodal drainage follows the perigastric chains (lesser and greater curvature) before reaching celiac, splenic, and porta hepatis nodes. Because the stomach is a mobile, fluid- and air-filled organ, daily volume and position vary, which complicates radiotherapy planning. The typical paradigm is surgery followed by adjuvant chemoradiation (INT-0116 regimen) for resected, node-positive or margin-positive disease, targeting the tumor bed and regional nodal basins.

Pancreatic Cancer

Roughly 60–70% of pancreatic adenocarcinomas arise in the head of the pancreas, where the tumor can compress the distal common bile duct as it passes through the pancreatic head — producing painless obstructive jaundice, dark urine, and pale (acholic) stools. This anatomic relationship is a frequent testable point: head-of-pancreas tumors present with jaundice because of biliary obstruction, not liver metastasis.

Resectability is determined by tumor contact with the superior mesenteric artery (SMA) , superior mesenteric vein (SMV) , celiac axis, and portal vein:

  • Category Vascular involvement
  • Resectable No arterial contact; ≤180° venous contact without contour irregularity
  • Borderline resectable Limited arterial abutment or reconstructible venous involvement
  • Locally advanced (unresectable) Encasement of SMA/celiac axis or unreconstructible venous occlusion

Head tumors are treated with a Whipple procedure (pancreaticoduodenectomy) when resectable; chemoradiation is used for borderline-resectable/locally advanced disease to attempt downstaging, and stereotactic body radiation therapy (SBRT) is increasingly used for locally advanced disease given the tight margins from bowel and duodenum.

Hepatocellular Carcinoma (HCC) and Liver Metastases

HCC arises almost exclusively in a background of chronic liver disease — cirrhosis from hepatitis B/C, alcohol use, or non-alcoholic fatty liver disease. Treatment selection depends on tumor burden and underlying liver function, quantified by the Child-Pugh score (bilirubin, albumin, INR, ascites, encephalopathy). SBRT and proton therapy are used for inoperable, well-selected lesions; whole-liver tolerance is limited, so highly conformal, hypofractionated approaches that spare uninvolved parenchyma are preferred over broad-field liver irradiation.